KR102128457B1 - Food composition for improvement of respiratory function - Google Patents

Abstract

The present specification relates to a composition for improving respiratory function and a method for manufacturing the same, including a mixed extract of a specific herbal medicine, and the composition in this specification contains natural products obtained from nature as an active ingredient, and has fewer side effects when applied to the human body, as well as bronchi. Since it has a remarkable effect on functional improvement, prevention and treatment of bronchial diseases, it can greatly help in alleviating the medical burden and improving the quality of life of patients with bronchial diseases.

Description

FOOD COMPOSITION FOR IMPROVEMENT OF RESPIRATORY FUNCTION

The present specification relates to a composition for improving respiratory function and a method for manufacturing the same, including a mixed extract of a specific herbal medicine.

Bronchitis is a disease that causes symptoms such as sputum and cough due to damage to the bronchial mucosa due to stimulation of viruses, bacteria, smoking, air pollution, dust, etc., and a large amount of inflammation and mucus. In general, bronchitis is divided into acute bronchitis and chronic bronchitis, and in severe cases, it may worsen with pneumonia or asthma.

Among bronchial diseases, asthma is a reversible obstructive airway disease with histological characteristics of inflammatory changes. It is a disease that exhibits paroxysmal dyspnea, cough, sputum, etc. by reversible airway contraction. It is caused by edema of mucous membranes and increased secretion of mucus. Among them, bronchosmooth muscle contraction is the main mechanism of development. The most prominent theory known to cause airway constriction is that airway hypersensitivity is caused by inhalation and ingestion of antigens, causing the airway to contract extensively. Other respiratory infections, inhalation of air or irritating gases contaminated with SO2, heavy metals, asbestos, dust, etc., rapid changes in climate, psychological stimulation, endocrine system abnormalities, autonomic nervous system abnormalities, physical exercise, β-receptor blockage And back. Chronic asthma and allergic asthma, known as the present disease, are known to be recurrent diseases, and these diseases are known to have a risk of recurrence by cytokines of immune cells and factors caused by autoimmune factors.

With the rapid industrialization, the air pollution problem is becoming more serious, and the bronchial disease problem caused by this threatens human health more and more. However, the therapy used for the treatment of bronchial disease has not yet achieved perfect results. These diseases are not only suffering from acute or chronic progression, but also high medical burden.

Meanwhile, bronchodilators and anti-inflammatory agents have been mainly used as treatments for conventional bronchial diseases, and emergency or severe patients have used oral steroids. However, when they stop using them, symptoms may worsen and there may be various side effects, such as shock, and there is an urgent need for natural improvement and therapeutic agents that can replace them.

Republic of Korea Registered Patent No. 10-1341532 (December 09, 2013)

The present specification aims to provide a composition for improving, preventing, and treating bronchial symptoms and bronchial diseases using natural-derived herbal medicines, and a method for manufacturing the same.

In order to solve the above problems, the present specification provides a composition for improving bronchial function comprising a mixed extract of bellflower, jujube, ginseng, dermis and licorice as an active ingredient.

In addition, the present specification is a method for preparing the composition, 1) 160-180 parts by weight of bellflower, 330-350 parts by weight of jujube, 150-170 parts by weight of ginseng, 220-240 parts by weight of dermis, and 90-110 parts by weight of licorice Extracting by; And 2) provides a method for producing a composition for improving bronchial function, comprising the step of concentrating so that the content of the soluble solid content is 60 to 70 Brix.

Since the composition in the present specification contains natural products obtained from nature as an active ingredient, it has not only few side effects when applied to the human body, but also has a remarkable effect on improving bronchial function, preventing and treating bronchial diseases, and can be widely applied to related fields. , It can greatly help in reducing the medical burden and improving the quality of life of patients with bronchial diseases.

1 is an animal model administered with physiological saline, an animal model administered with physiological saline and ovalbumin, an animal model administered with ovalbumin and the composition of Example 1, and an animal model administered with the composition of Example 2 with ovalbumin. It shows the degree of stenosis of the bronchus and the infiltration pattern of inflammatory cells.
2 briefly shows an example of a manufacturing process for Examples 1 and 2.

In the present specification, "extract" includes all substances obtained by extracting the components of a natural product, regardless of an extraction method, an extraction solvent, an extracted component or a form of an extract, and also extracts a substance obtained by extracting a component obtained by extracting a component of a natural product. It is a broad concept that includes all materials that can be obtained by processing or processing by a method, and specifically, the processing or processing may be additionally fermenting or enzymatically treating the extract. Therefore, the extract herein is a broad concept including fermentation products, concentrates, and dried products.

In the present specification, “viscous beverage” is a beverage having a certain viscosity, and when the packaging material is opened or the packaging material is scratched and squeezed, the beverage inside the packaging material flows through the opened place or scratches, and the consumer separates the container or device. It is a beverage that has a concentration and viscosity suitable for direct consumption without spilling without it.

In the present specification, “viscous syrup” is a syrup having a certain viscosity, and when the packaging material is opened or scratched on the packaging material to squeeze the syrup inside the packaging material, it flows through the opened place or scratches, and the consumer separates the container or device. It is a syrup that has a concentration and viscosity suitable for direct consumption without spilling.

In the present specification, "jujube extract concentrate" is a substance that re-concentrates the extract obtained by extracting jujube with hot water, and is also called jujube extract or jujube concentrate.

In the present specification, “bronchi-related efficacy” refers to an effect of improving, preventing and treating one or more selected from the group consisting of abnormal symptoms, pathological symptoms, symptoms related to bronchial diseases, and bronchial diseases themselves, which appear in the respiratory tract, such as the trachea or bronchi. Speak ability.

In the present specification, "improvement of bronchial function" refers to one or more improvements selected from the group consisting of abnormal symptoms, pathological symptoms, symptoms related to bronchial diseases, and bronchial diseases themselves, and the role of the bronchial body through it. Recovery of function.

“Pharmaceutically acceptable” herein means approval by the government or equivalent regulatory agency that it can be used in animals, more specifically in humans, by avoiding significant toxic effects when used in conventional medicinal dosages. It means that it can be received or approved, or it is recognized as listed in the pharmacopeia or described in other general pharmacopoeia.

“Pharmaceutically acceptable salt” as used herein refers to a salt according to one aspect of the present invention having pharmacologically acceptable and desirable pharmacological activity of a parent compound. The salt (1) is formed of an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; Or acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) Benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-Toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo [2,2,2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert Acid addition salts formed from organic acids such as butylacetic acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid; Or (2) a salt formed when the acidic proton present in the parent compound is substituted.

In one aspect, the present invention is a composition for improving bronchial function comprising a mixed extract of bellflower, jujube, ginseng, dermis and licorice as an active ingredient.

As one embodiment, the mixed extract is 160 to 180 parts by weight of the bellflower, 330 to 350 parts by weight of the jujube, 150 to 170 parts by weight of the ginseng, 220 to 240 parts by weight of the dermis and 90 to 110 parts by weight of the licorice It may be extracted.

In another aspect, the present invention is a method for preparing the composition, 1) 160-180 parts by weight of bellflower, 330-350 parts by weight of jujube, 150-170 parts by weight of ginseng, 220-240 parts by weight of dermis, and 90-110 parts by weight of licorice Mixing and extracting parts; And 2) concentrating the content of the soluble solid content to 60 to 70 Brix.

As an embodiment, the preparation method comprises: 3) mixing the jujube extract concentrate having a content of soluble solids of 60 to 70 brix; And 4) adding purified water to adjust the content of the soluble solid content to be 50 to 55 Brix.

In one aspect, the extraction may be hot water extraction. However, the hot water may be a mixture of C1 to C5 lower alcohols such as ethanol.

In one aspect, the bellflower is 160 parts by weight or more, 162 parts by weight or more, 164 parts by weight or more, 166 parts by weight or more, 168 parts by weight or more, 170 parts by weight or more, 172 parts by weight or more, 174 parts by weight or more, 176 parts by weight Or more than 178 parts by weight. In another aspect, the bellflower is 180 parts by weight or less, 178 parts by weight or less, 176 parts by weight or less, 174 parts by weight or less, 172 parts by weight or less, 170 parts by weight or less, 168 parts by weight or less, 166 parts by weight or less, 164 parts by weight or less Or 162 parts by weight or less. If the bellflower is less than 160 parts by weight or more than 180 parts by weight, broncho-related efficacy may be significantly reduced.

In one aspect, the date is 330 parts by weight or more, 332 parts by weight or more, 334 parts by weight or more, 336 parts by weight or more, 338 parts by weight or more, 340 parts by weight or more, 342 parts by weight or more, 344 parts by weight or more, 346 parts by weight or more Or 348 parts by weight or more. In another aspect, the jujube is 350 parts by weight or less, 348 parts by weight or less, 346 parts by weight or less, 344 parts by weight or less, 342 parts by weight or less, 340 parts by weight or less, 338 parts by weight or less, 336 parts by weight or less, 334 parts by weight or less Or less or 332 parts by weight. If the jujube is less than 330 parts by weight or more than 350 parts by weight, broncho-related efficacy may be significantly reduced.

In one aspect, the ginseng may be dried, 150 parts by weight or more, 152 parts by weight or more, 154 parts by weight or more, 156 parts by weight or more, 158 parts by weight or more, 160 parts by weight or more, 162 parts by weight or more, 164 parts by weight Parts or more, 166 parts by weight or more, or 168 parts by weight or more. In another aspect, the ginseng is 170 parts by weight or less, 168 parts by weight or less, 166 parts by weight or less, 164 parts by weight or less, 162 parts by weight or less, 160 parts by weight or less, 158 parts by weight or less, 156 parts by weight or less, 154 parts by weight Or less or 152 parts by weight. When the dried ginseng is less than 150 parts by weight or more than 170 parts by weight, broncho-related efficacy may be significantly reduced.

In one aspect, the dermis is 220 parts by weight or more, 222 parts by weight or more, 224 parts by weight or more, 226 parts by weight or more, 228 parts by weight or more, 230 parts by weight or more, 232 parts by weight or more, 234 parts by weight or more, 236 parts by weight Or more than 238 parts by weight. In another aspect, the dermis is 240 parts by weight or less, 238 parts by weight or less, 236 parts by weight or less, 234 parts by weight or less, 232 parts by weight or less, 230 parts by weight or less, 228 parts by weight or less, 226 parts by weight or less, 224 parts by weight or less Or less or 222 parts by weight. When the dermis is less than 220 parts by weight or more than 240 parts by weight, broncho-related efficacy may be significantly reduced.

In one aspect, the licorice is 90 parts by weight or more, 92 parts by weight or more, 94 parts by weight or more, 96 parts by weight or more, 98 parts by weight or more, 100 parts by weight or more, 102 parts by weight or more, 104 parts by weight or more, 106 parts by weight or more Or more than 108 parts by weight. In another aspect, the licorice is 110 parts by weight or less, 108 parts by weight or less, 106 parts by weight or less, 104 parts by weight or less, 102 parts by weight or less, 100 parts by weight or less, 98 parts by weight or less, 96 parts by weight or less, 94 parts by weight Or less or 92 parts by weight. If the licorice content is less than 90 parts by weight or more than 110 parts by weight, the efficacy of bronchoscopy may be significantly reduced.

As another embodiment, the bellflower may be roasted. When roasted bellflower is used, it can exhibit a more remarkable effect in terms of improving bronchial function, as identified by the following experimental example.

As another embodiment, the mixed extract may have a soluble solids content of 60 to 70 Brix. In one aspect, the content may be 60 Briggs or more, 62 Briggs or more, 64 Briggs or more, 66 Briggs or more, 68 Briggs or more, or 69 Briggs or more. In other aspects, the content may be 70 Briggs or less, 68 Briggs or less, 66 Briggs or less, 64 Briggs or less, 62 Briggs or less, or 61 Briggs or less. In the mixed extract, when the content of the soluble solid content is less than 60 brix, broncho-related efficacy may be significantly reduced, and when it exceeds 70 brix, broncho-related efficacy may be deteriorated and remarkable reduction in preference may be caused.

As another embodiment, the composition may further include a jujube extract concentrate. The jujube extract concentrate may be an active ingredient for reducing rejection and increasing preference when ingesting, or may be an effective ingredient for amplifying broncho-related efficacy.

In one aspect, the jujube extract may be a hot water extract, the jujube extract concentrate may be a concentrated hot water extract, and the hot water may include some lower alcohols of C1 to C5 such as ethanol.

As another embodiment, the jujube extract concentrate may have a content of soluble solids of 60 to 70 brix. In one aspect, the content may be 60 Briggs or more, 62 Briggs or more, 64 Briggs or more, 66 Briggs or more, 68 Briggs or more, or 69 Briggs or more. In other aspects, the content may be 70 Briggs or less, 68 Briggs or less, 66 Briggs or less, 64 Briggs or less, or 62 Briggs or less.

As an embodiment, the weight ratio of the mixed extract and the jujube extract concentrate may be 1: 3 to 5. In one aspect, the weight ratio is 1:3 or more, 1:3.2 or more, 1:3.4 or more, 1:3.6 or more, 1:3.8 or more, 1:4 or more, 1:4.2 or more, 1:4.4 or more, 1:4.6 Or more, 1:4.8 or more. In another aspect, the weight ratio is 1:5 or less, 1:4.8 or less, 1:4.6 or less, 1:4.4 or less, 1:4.2 or less, 1:4 or less, 1:3.8 or less, 1:3.6 or less, 1:3.4 Hereinafter, it may be 1:3.2 or less. When the jujube extract concentrate (jujube extract) is included in the soluble solid content range as described above, in the weight ratio described above, while maintaining the efficacy related to the bronchus, the preference for taste or aroma is significantly improved. When the weight ratio is less than 1:3 or greater than 1:5, a significant decrease in palatability such as taste, aroma, and viscosity may be caused.

As another embodiment, the composition may have a content of soluble solids of 50 to 55 brix. In one aspect, the content of the soluble solids may be 50 Briggs or more, 51 Briggs or more, 52 Briggs or more, 53 Briggs or more, or 54 Briggs or more. In another aspect, the content of the soluble solids may be 55 Briggs or less, 54 Briggs or less, 53 Briggs or less, 52 Briggs or less, or 51 Briggs or less. When the content of the soluble solid content is less than 50 brix, the viscosity is excessively low, and when squeezing the packaging material for packaging the composition, there is a problem that it is very difficult to take it directly, and when it exceeds 55 brix, the viscosity is excessively high. It can cause problems such as difficulty, residual feeling in the mouth (feeling left in the mouth), and difficulty swallowing.

As another embodiment, the composition may be a food composition.

The food composition may include a health food composition, and may be a liquid, sol, gel, or solid state formulation. For example, there are various foods, beverages, gums, teas, vitamin complexes, health functional foods, and dietary supplements, and may be used in the form of powders, granules, tablets, capsules, or beverages. The food composition of each formulation can be formulated by appropriately selecting the ingredients commonly used in the field other than the active ingredient according to the formulation or purpose of use without difficulty, and synergistic effects may occur when applied simultaneously with other raw materials. The food, preferably, may be a beverage base or a viscous beverage.

There are no particular limitations on the additional ingredients that may be included in addition to the active ingredients disclosed in the present specification, and may include various flavoring agents or natural carbohydrates, etc., as additional ingredients, such as conventional drinks. Examples of the natural carbohydrate include monosaccharides, disaccharides such as glucose and fructose, polysaccharides such as maltose and sucrose, sugars such as xylitol, sorbitol, and erythritol, such as polysaccharides such as dextrin and cyclodextrin. And so on. As the above-mentioned flavoring agent, natural flavoring agents (taumatine, stevia extract (e.g., rebaudioside A, glycyrrhizine, etc.) and synthetic flavoring agents (e.g., saccharin, aspartame, etc.) can be advantageously used. The ratio of the natural carbohydrate may be about 1 to 20 g per 100 ml of the composition disclosed herein, and about 5 to 12 g in one aspect.

The food composition is, in one aspect, various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and neutralizing agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof , Organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonic acid used in carbonated beverages, and the like. In other aspects it may include flesh for the manufacture of natural fruit juices and vegetable drinks. The components can be used independently or in combination. The ratio of the additive may vary, but is generally selected from 0.001 to about 20 parts by weight per 100 parts by weight of the composition disclosed herein.

As an embodiment, the composition may be a pharmaceutical composition for the prevention and treatment of bronchial disease.

In one aspect, the bronchial disease is at least one bronchitis selected from the group consisting of acute bronchitis, chronic bronchitis, allergic bronchitis, infectious bronchitis, traumatic bronchitis, catarrhal bronchitis, purulent bronchitis, obstructive bronchitis, ulcerative bronchitis and invasive bronchitis, It may be one or more selected from the group consisting of asthma, and bronchial tuberculosis.

In another aspect, the symptoms due to the bronchial disease may be one or more selected from the group consisting of cough, sputum, bronchial stenosis, bronchial pain, bronchial contraction, dyspnea due to bronchial disease, and bronchial collapse.

In one aspect, the pharmaceutical composition may further contain preservatives, preservatives, stabilizers, hydration or emulsification accelerators, pharmaceutical adjuvants such as salts and/or buffers for osmotic pressure control, and other therapeutically useful substances, It can be formulated in a variety of oral or parenteral dosage forms according to conventional methods.

In another aspect, the pharmaceutical composition may further include a pharmaceutically acceptable salt for preservation and enhancement of effect.

Examples of the oral administration agent include tablets, pills, hard and soft capsules, liquids, viscous syrups, suspensions, emulsifiers, syrups, powders, powders, granules, granules, and pellets, and these formulations are effective ingredients. In addition to surfactants, diluents (e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine), lubricants (e.g. silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycols) can do. Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, and optionally starch, agar, alginic acid or its sodium salt It may contain pharmaceutical additives such as disintegrants, absorbents, colorants, flavoring agents, and sweetening agents. The tablets can be prepared by conventional mixing, granulating or coating methods.

In addition, the parenteral dosage form, for example, may be a formulation such as injection, drop, ointment, lotion, gel, cream, spray, suspension, emulsion, suppository, patch, etc. It is not.

The pharmaceutical composition may be administered by oral, parenteral, rectal, topical, transdermal, subcutaneous, etc., but is preferably administered orally.

Determination of the dosage of the active ingredient is within the level of a person skilled in the art, and the daily dosage of the drug may vary according to various factors such as the degree of progression, onset time, age, health condition, and complications of the subject to be administered.

When the formulation according to one aspect of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butylglycol oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan.

When the formulation according to one aspect of the present invention is a suspension, a liquid diluent such as water, ethanol or propylene glycol as a carrier component, an ethoxylated isostearyl alcohol, a suspension agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester , Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or trakant, and the like.

It may be desirable that the formulation of the pharmaceutical composition is a viscous syrup.

As another embodiment, the daily dosage of the pharmaceutical composition may be 0.001 to 50 mg/kg/day. In one aspect, 0.001 mg/kg/day or more, 0.005 mg/kg/day or more, 0.01 mg/kg/day or more, 0.05 mg/kg/day or more, 0.1 mg/kg/day or more, 0.15 mg/kg/day or more Above, above 0.2 mg/kg/day, above 0.25 mg/kg/day, above 0.3 mg/kg/day, above 0.33 mg/kg/day, above 0.35 mg/kg/day, above 0.4 mg/kg/day, 0.5 mg/kg/day or more, 0.6 mg/kg/day or more, 0.7 mg/kg/day or more, 0.8 mg/kg/day or more, 0.9 mg/kg/day or more, 1 mg/kg/day or more, 2 mg or more Above /kg/day, above 3 mg/kg/day, above 4 mg/kg/day, above 5 mg/kg/day, above 6 mg/kg/day, above 7 mg/kg/day, above 8 mg/kg More than /day, more than 10mg/kg/day, more than 15 mg/kg/day, more than 20 mg/kg/day, more than 30 mg/kg/day, more than 40 mg/kg/day or more than 45 mg/kg/day Can. In another aspect, the daily dosage is 50 mg/kg/day or less, 30 mg/kg/day or less, 25 mg/kg/day or less, 20 mg/kg/day or less, 10 mg/kg/day or less, 9 Below mg/kg/day, below 8 mg/kg/day, below 7 mg/kg/day, below 6 mg/kg/day, below 5 mg/kg/day, below 4 mg/kg/day, below 3 mg/ Below kg/day, below 2 mg/kg/day, below 1 mg/kg/day, below 0.9 mg/kg/day, below 0.8 mg/kg/day, below 0.7 mg/kg/day, below 0.6 mg/kg/ less than day, less than 0.5 mg/kg/day, less than 0.4 mg/kg/day, less than 0.35 mg/kg/day, less than 0.33 mg/kg/day, less than 0.3 mg/kg/day, less than 0.25 mg/kg/day , 0.2 mg/kg/day or less, 0.15 mg/kg/day or less, 0.1 mg/kg/day or less, 0.08 mg/kg/day or less, or 0.05 mg/kg/day or less. When the daily dose is less than 0.001 mg/kg/day, the efficacy is insufficient or ineffective, and when it exceeds 50 mg/kg/day, it has similar efficacy to that of 50 mg/kg/day, which is not effective.

Hereinafter, one aspect of the present invention will be described in detail with reference to preparation examples, examples, experimental examples, and formulation examples. However, the following examples are only for illustrating an aspect of the present invention, and the scope of the present invention is not limited to these examples.

[Production Example 1] Preparation of beverage concentrate using herbal ingredients

Functional beverage concentrates (or functional beverage bases) were prepared using specific herbal medicines and food ingredients readily available on the market.

Specifically, the process of extracting the appropriate amount of purified water into a mixture of 1000 g of bellflower 170 g, jujube 340 g, ginseng 160 g, dermis 230 g, and licorice 100 g in a total amount of 1000 g for 2 hours at 100°C for 3 hours was extracted twice. It was carried out to prepare an extract. At this time, the bellflower was roasted, and the ginseng was dried. Subsequently, the extract is concentrated by vacuum evaporation at 4° C. for 24 hours (but not limited to this as an example of a concentration method), so that the content of soluble solids is 60 Brix% or more (preferably 65 Brix). To be reached. Thereafter, the functional beverage concentrate (or functional beverage base, Example 1) completed through the aging process was stored in a cool place.

[Production Example 2] Preparation of viscous beverage containing the concentrate of Preparation Example 1

A viscous beverage was prepared using the functional beverage concentrate (or functional beverage base) of Preparation Example 1 and a jujube extract.

Specifically, the functional beverage concentrate (or functional beverage base) of Preparation Example 1 and jujube extract (or jujube concentrate) were mixed in a weight ratio of 1:3 to 5 (preferably 1:4). At this time, the jujube extract was a hot water extract of jujube, and the content of soluble solids in the jujube extract was 60 to 70 brix (preferably 65 brix). Thereafter, purified water was added to the mixture to adjust the content of soluble solids to 50 to 55 Brix, and aged at 4° C. for 3 days (Example 2).

Since the completed viscous beverage had a soluble solid content of 50 Briggs or more, microbial growth was inhibited, and it was confirmed that the viscous beverage has an appropriate viscosity that can be consumed by consumers when packaged in a squeezed form. When the soluble solids content of the finished viscous beverage by changing the amount of purified water is 49.9 brix or less, the viscosity is too weak, so it is difficult to ingest when packaged in a squeezed form, and the microorganisms multiply, causing problems in hygiene and safety. Confirmed. In addition, if the soluble solid content is 55.1 Briggs or more by adjusting the purified water content, the viscous and elasticity is excessive, so that the texture may be bad or the mouth may remain ingested, there is a risk of airway obstruction, and inefficient absorption due to insufficient moisture may be a problem. It was confirmed that it may.

[Comparative Example] Preparation of Comparative Composition for Experiment

In order to compare the results of Examples 1 and 2 (Examples 1 and 2) with the experimental results, the same examples were prepared as in Preparation Example 2, but Comparative Examples were prepared by changing raw materials and composition as shown in Table 1 below. .

division Changes in raw materials and composition Comparative Example 1 Excluding bellflower from the mixture raw material of Preparation Example 1 Comparative Example 2 Jujube is excluded from the raw material of the mixture of Preparation Example 1 Comparative Example 3 Ginseng is excluded from the mixture raw materials of Preparation Example 1. Comparative Example 4 The dermis is excluded from the mixture of Preparation Example 1 Comparative Example 5 Licorice is excluded from the mixture raw materials of Preparation Example 1. Comparative Example 6 Among the raw materials of the mixture of Preparation Example 1, bellflower was used without being roasted. Comparative Example 7 Add 150 g of astragalus to the mixture raw material of Preparation Example 1 Comparative Example 8 Add 150g soybean to the mixture raw material of Preparation Example 1 Comparative Example 9 150 to 159 g of bellflower is used in the mixture raw material of Preparation Example 1 Comparative Example 10 181 to 190 g of bellflower is used in the mixture raw material of Preparation Example 1 Comparative Example 11 Among the raw materials of the mixture of Preparation Example 1, 310 to 329 g of jujube are used. Comparative Example 12 Among the raw materials of the mixture of Preparation Example 1, 351 to 370 g of jujube are used. Comparative Example 13 140 to 149 g of ginseng is used in the mixture raw material of Preparation Example 1 Comparative Example 14 171 to 175 g of ginseng is used in the mixture of Preparation Example 1 Comparative Example 15 200 to 219 g of dermis is used in the mixture of Preparation Example 1 Comparative Example 16 241 to 250 g of dermis is used in the mixture of Preparation Example 1 Comparative Example 17 80 to 89 g of licorice is used in the mixture raw material of Preparation Example 1 Comparative Example 18 111-120 g of licorice from the mixture raw material of Preparation Example 1 was used Comparative Example 19 The content of soluble solids in the result of Preparation Example 1 was adjusted to 55 to 59.9 brix. Comparative Example 20 The content of soluble solids in the result of Preparation Example 1 was adjusted to 70.1 to 75 Brix Comparative Example 21 Adjust the soluble solid content in the result of Preparation Example 2 to 45 to 49.9 Comparative Example 22 The soluble solid content in the result of Preparation Example 2 was adjusted to 55.1 to 60 Comparative Example 23 Adjust the soluble solid content in jujube extract to 55 to 59.9 brix Comparative Example 24 The content of soluble solids in jujube extract is adjusted to 70.1 to 75 brix Comparative Example 25 The weight ratio of the resultant of Preparation Example 1 and the jujube extract is adjusted to 1: 2 to 2.9. Comparative Example 26 The weight ratio of the result of Preparation Example 1 and the date palm extract is adjusted to 1: 5.1 to 6

[Experimental Example 1] Evaluation of the effect on bronchial tissue inflammation

Whether the bronchial function was improved with the concentrates according to Preparation Examples 1 and 2 (Example 1) and viscous beverages (Example 2) were tested.

First, females of BALB/C 8-week-old mice were purchased from and used, and Ovalbumin, alum, etc. were purchased and used by SIGMA (St. Louis, USA). 20-ug/mouse egg albumin (ovalbumin, OVA, Sigma) adsorbed with aluminum hydroxide (alum) on the 1st and 15th days of 6 to 8 week old female BALB/c mice (Orient Bio Co., Ltd., Seongnam, Gyeonggi-do) Sensitized by intraperitoneal injection, and re-sensitized 3 times by OVA spraying on the mouse after 7 days to make a bronchial asthma animal model.

The bronchial asthma animal model was orally administered with the results according to Preparation Examples 1 and 2 (Examples 1 and 2) at 0.1 mg/kg for 7 days. The control group was administered orally with physiological saline.

For biopsy, after performing BAL, a fixative (4% paraformaldehyde in PBS) was injected into the lavage catheter, and the lung tissue was removed to fix it for another 4 hours. Subsequently, this was put into paraffin, stained with 4 sections hematoxylineosin (H&E), and examined.

Allergic bronchial asthma causes stenosis of the airways and infiltration of inflammatory cells in the bronchus and formation of goblet cells, secreting mucus, and deposition of collagen is prominent. Bronchials administered with Examples 1 and 2 appeared similar to the normal population , And showed a markedly reduced pattern of airway stenosis and inflammatory cell infiltration (FIG. 1).

[Experimental Example 2] Airway resistance measurement

Airway resistance values were measured after oral administration of saline, Examples 1, 2, and Comparative Examples 1 to 26 in 0.1 mg/kg for 7 days to the bronchial asthma animal model of Experimental Example 1. Airway resistance was measured by a conventional research method using one chamber plethysmography (All Medicus, Seoul). The degree of airway resistance was evaluated by measuring enhanced pause (Penh). Penh is measured by placing the mouse in the chamber, measuring the basal value in normal breathing state, and then inhaling PBS for 5 minutes using a nebulizer and measuring for 3 minutes. Thereafter, methacholine (methacholine, Sigma, St. Louis, MO) was gradually increased to a concentration of 3, 6, 12, 25, 50 mg/ml, and then the average value of Pehn was measured after inhalation. Pehn, used as an indicator of airway resistance, is proportional to the ratio of peak expiratory flow (PEF)/peak inspiratory flow (PIF) to the period of breathing and the expiratory volume of the first expiratory volume. It is expressed as a number of dimensions and has a good correlation with airway resistance and is known as an indicator of airway contraction.

Penh=(Te/RT-1)(PEF/PIF)

(Te=expiratory time,RT=relaxation time,PEF=peak expiratory flow,PIF=peak inspiratory flow)

As a result, as shown in Table 2, it was found that Examples 1 and 2 can significantly reduce respiratory distress by significantly reducing airway resistance.

division Bronchial asthma model Control
(saline administration group) Example 1 Example 2 Comparative Examples 1 to 26 Penh at metacholine 12mg/ml 2.5 2.5 0.6 0.8 2.1 to 2.3 Penh at 25 mg/ml methacholine 4.2 4.3 1.5 2.0 3.6 to 3.9 Penh at 50 mg/ml methacholine 8 7.9 2.1 2.3 6.0 to 6.5

[Experimental Example 3] Evaluation of the effect of improving bronchial function

80 people in their 20s and 40s who usually have bronchial symptoms such as coughing and sputum, mainly for instructors, salespersons, etc., who have a lot of throat (including acute bronchitis, chronic bronchitis, infectious bronchitis, catarrhal bronchitis, purulent bronchitis, Obstructive bronchitis, ulcerative bronchitis, infiltrative bronchitis, asthma, and patients suffering from bronchial tuberculosis are also included.) and 20 mg of each of Examples 1, 2 and Comparative Examples 1 to 26 is taken once a day Ordered. Then, after one month, the subject's coughing, sputum, sore throat, and bronchial tickling improved according to the level of 5-complete improvement, 4-significant improvement, 3-moderate improvement, 2-slight improvement, and 1-no improvement. The improvement effect was evaluated, and the average value is shown in Table 3 below.

division cough Phlegm Neck rest Bronchial tickling Before consumption One One One One Example 1 5 4.8 5 4.7 Example 2 4.8 4.7 4.8 4.5 Comparative Examples 1 to 26 1 to 1.6 1.2 to 1.8 1.4 to 1.6 2 to 2.1

[Experimental Example 4] Sensory evaluation

Sensory evaluations of taste, aroma, viscosity, and overall palatability of the examples and comparative examples were carried out. The sensory evaluation was evaluated by 20 adult males and 20 adult females by the 9-point scoring method (9-very good, 7-good, 5-normal, 3-bad, 1-very bad). Overall preference is averaged for scores of taste, aroma and viscosity.

The results are shown in Table 4 below, and it was found that Example 2 was most suitable as a viscous beverage to squeeze.

division flavor incense Viscosity Full preference diagram Example 1 4 5 4 4.33 Example 2 8 8.5 9 8.50 Maximum value among Comparative Examples 1 to 22 6.5 6 7.5 6.67 Average values of Comparative Examples 1 to 22 6.2 5.6 6.4 6.06 Comparative Example 23 6 6 6.5 6.17 Comparative Example 24 8 5 7.5 6.83 Comparative Example 25 6 6 4.5 5.50 Comparative Example 26 7 5 7 6.33

[Formulation Example 1] Beverage base

The Example 1 and food preservative (for example, sodium benzoate) 0.001mg was put in a packaging material to prepare a beverage base product for the preparation of a beverage for improving bronchial function.

[Formulation Example 2] Viscous drink and viscous syrup

The Example 2 was sealed in a stick-type packaging material to prepare a viscous beverage and viscous syrup product.

The above, Preparation Examples, Examples, Experimental Examples and Formulation Examples are only for illustrating one aspect of the present invention, it is obvious that the scope of the present invention is not limited to these examples.

Claims (19)

Contains a mixed extract of bellflower, jujube, ginseng, dermis and licorice as an active ingredient,
The mixed extract is 170 parts by weight of the bellflower, 340 parts by weight of the jujube, 160 parts by weight of the ginseng, 230 parts by weight of the dermis and 100 parts by weight of the licorice extract for improving bronchial function. According to claim 1, The mixed extract is a hot water extract, food composition. delete The food composition of claim 1, wherein the bellflower is roasted. The food composition of claim 1, wherein the mixed extract has a soluble solid content of 65 Brix. The food composition of claim 1, further comprising a jujube extract concentrate. delete The food composition of claim 6, wherein the jujube extract concentrate has a content of soluble solids of 65 brix. According to claim 6, The weight ratio of the mixed extract and the jujube extract concentrate is 1: 4, food composition. The food composition according to claim 6, wherein the content of the soluble solid content is 50 to 55 brix. delete The food composition of claim 1, wherein the food is a beverage base or a viscous beverage. delete delete delete delete delete As a method of manufacturing a food composition for improving bronchial function comprising a mixed extract of bellflower, jujube, ginseng, dermis and licorice as an active ingredient,
1) 160 to 180 parts by weight of bellflower, 330 to 350 parts by weight of jujube, 150 to 170 parts by weight of ginseng, 220 to 240 parts by weight of dermis, and 90 to 110 parts by weight of licorice; And
2) concentrating so that the content of soluble solid content is 60 to 70 Brix;
A method of manufacturing a food composition for improving bronchial function, comprising a. The method of claim 18,
3) mixing the jujube extract concentrate having a soluble solid content of 60 to 70 brix; And
4) adding purified water to adjust the content of soluble solids to be 50 to 55 Brix;
The manufacturing method further comprising a.

Images